Over the last 12 months, six Altimmune, Inc. executives and directors added shares on the open market, about $370,000 in total, and none of them sold.
Biggest single buyer: Durso Jerome Benedict, CEO, with roughly $71,000. Notably, at least one C-suite executive was among the buyers.
4 quarters in a row of net buying by insiders. Insiders bought in 5 of the last 7 full quarters. Big money check: 210 institutions held ALT as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Durso Jerome Benedict | CEO | Buy | 15,000 | $2.95 | $44K | SEC |
| Apr 6, 2026 | GILL JOHN | Director | Buy | 9,200 | $3.41 | $31K | SEC |
| Apr 1, 2026 | WEAVER GREGORY L | CFO | Buy | 10,000 | $3.15 | $32K | SEC |
| Apr 1, 2026 | Durso Jerome Benedict | CEO | Buy | 15,000 | $3.14 | $47K | SEC |
| Mar 9, 2026 | WEAVER GREGORY L | CFO | Buy | 5,000 | $3.54 | $18K | SEC |
| Mar 9, 2026 | Durso Jerome Benedict | CEO | Buy | 20,000 | $3.54 | $71K | SEC |
| Jan 9, 2026 | Pisano Wayne | Director | Buy | 5,000 | $4.08 | $20K | SEC |
| Jan 5, 2026 | Sohn Catherine A. | Director | Buy | 500 | $4.24 | $2K | SEC |
| Dec 29, 2025 | Jorkasky Diane | Director | Buy | 527 | $3.80 | $2K | SEC |
| Dec 23, 2025 | GILL JOHN | Director | Buy | 12,500 | $4.10 | $51K | SEC |
| Dec 22, 2025 | Durso Jerome Benedict | Director | Buy | 12,500 | $4.13 | $52K | SEC |
| Mar 18, 2025 | Sohn Catherine A. | Director | Buy | 1,000 | $5.78 | $6K | SEC |
| Mar 14, 2025 | WEAVER GREGORY L | CFO | Buy | 10,000 | $5.20 | $52K | SEC |
| Aug 20, 2024 | Drutz David | Director | Sell | 7,827 | $6.93 | $54K | SEC |
| Aug 20, 2024 | Drutz David | Director | Sell | 8,184 | $6.88 | $56K | SEC |
In the last 12 months Altimmune, Inc. insiders made open-market purchases worth about $370,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ALT was filed on 2026-08-13.
210 investment managers reported holding ALT in SEC Form 13F filings for Q2 2026.
No congressional trades in ALT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).